Needham & Company LLC lowered shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) from a buy rating to a hold rating in a report released on Friday, Marketbeat reports.
LXRX has been the topic of several other reports. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, January 31st. BidaskClub raised shares of Lexicon Pharmaceuticals from a strong sell rating to a sell rating in a research report on Saturday, January 20th. ValuEngine downgraded shares of Lexicon Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, February 2nd. JPMorgan Chase & Co. downgraded shares of Lexicon Pharmaceuticals from a neutral rating to an underweight rating and lowered their price objective for the stock from $15.00 to $10.00 in a research report on Wednesday, February 14th. Finally, Wedbush reissued an outperform rating and set a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research report on Thursday, November 30th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $24.80.
Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) traded down $0.58 during trading on Friday, reaching $8.27. 1,239,335 shares of the company’s stock traded hands, compared to its average volume of 675,948. Lexicon Pharmaceuticals has a 52 week low of $7.80 and a 52 week high of $18.00. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. The stock has a market cap of $815.98, a P/E ratio of -6.56 and a beta of 0.24.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 142.86% and a negative return on equity of 125.02%. The company had revenue of $33.05 million for the quarter, compared to the consensus estimate of $29.84 million. During the same period last year, the firm posted ($0.31) EPS. Lexicon Pharmaceuticals’s revenue for the quarter was up 43.7% on a year-over-year basis. sell-side analysts anticipate that Lexicon Pharmaceuticals will post -1.08 earnings per share for the current year.
Several large investors have recently modified their holdings of the company. MetLife Investment Advisors LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at about $236,000. Jump Trading LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at about $104,000. Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Lexicon Pharmaceuticals by 29.8% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 417,856 shares of the biopharmaceutical company’s stock valued at $4,128,000 after acquiring an additional 95,900 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Lexicon Pharmaceuticals by 56.6% in the fourth quarter. Two Sigma Investments LP now owns 176,221 shares of the biopharmaceutical company’s stock valued at $1,741,000 after acquiring an additional 63,672 shares in the last quarter. Finally, Two Sigma Advisers LP purchased a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter valued at about $104,000.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://transcriptdaily.com/2018/02/24/lexicon-pharmaceuticals-lxrx-downgraded-by-needham-company-llc-to-hold.html.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.